Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi

The authors wish to make the following corrections to their article:

Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1

Download article

Share this article

Article Details

Article Type

Corrigendum

DOI

10.7573/dic.2021-5-2

Original article

Download article

Share this article

Keywords

Categories

Publication Dates

Published: .

Article Views

Monthly article views (last 11 months)

Drugs in Context PubMed Central
Source HTML views PDF downloads Totals
Drugs in Context since September 15, 2025 9 0 9
PubMed Central since November 1, 2024 14 0 14
Totals 23 0 23

Related Articles

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.